PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast Cancer

Sponsor
Beijing Biostar Technologies, Ltd (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05052437
Collaborator
Chengdu Biostar Pharmaceuticals, Ltd (Other)
16
2
2
14.3
8
0.6

Study Details

Study Description

Brief Summary

This trial is an open, multi-center, phase Ic clinical study on the pharmacokinetics and drug interactions of utidelone injection combined with capecitabine in patients with recurrent and metastatic breast cancer.

The purpose of this trial is:
  1. To evaluate the pharmacokinetic characteristics of continuous intravenous administration of utidelone.

  2. To evaluate the drug interaction of utidelone and capecitabine.

Condition or Disease Intervention/Treatment Phase
Phase 1

Study Design

Study Type:
Interventional
Anticipated Enrollment :
16 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Open, Multicenter, Phase Ic Clinical Study on the Pharmacokinetics and Drug Interactions of Utidelone Plus Capecitabine in Patients With Recurrent and Metastatic Breast Cancer
Actual Study Start Date :
Oct 22, 2020
Anticipated Primary Completion Date :
Oct 31, 2021
Anticipated Study Completion Date :
Dec 31, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Utidelone

Drug: Utidelone
8 patients will be assigned to utidelone arm and receive utidelone injection 30 mg/m2/day intravenously, once a day for 5 consecutive days in a 21-day cycle.

Experimental: Utidelone plus capecitabine

Drug: Utidelone Injection; capecitabine
8 patients will be assigned to utidelone plus capecitabine arm receiving utidelone plus capecitabine. Utidelone injection 30mg/m2/day, intravenously administered once a day for 5 consecutive days; capecitabine tablets, 1000mg/m2, orally, 2 times a day for 14 consecutive days. 21 days is a cycle

Outcome Measures

Primary Outcome Measures

  1. Peak Plasma Concentration (Cmax) [12 weeks]

    To measure the maximal plasma concentration of the study drugs and evaluate the pharmacokinetic characteristics of continuous intravenous administration of utidelone, measure PK parameters such as Maximum Plasma Concentration [Cmax]

  2. C-T curve [12 weeks]

    To evaluate the pharmacokinetic interaction of utidelone and capecitabine in patients when administered in combination.

  3. Area under the plasma concentration versus time curve (AUC) [12 weeks]

    To get area under the plasma concentration versus time curve

Secondary Outcome Measures

  1. Measure and plot r-t curve [12 weeks]

    To analyse mass balance

  2. Incidence of treatment-related adverse events as assessed by CTCAE v4.0 [6 months]

    To evaluate the safety of the study

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  1. Voluntarily sign an informed consent form, have good compliance, and cooperate with relevant inspections.

  2. Histologically and/or cytologically diagnosed patients with advanced, metastatic breast cancer.

  3. Patients who have previously received at least one anthracycline and taxane drug therapy (neoadjuvant therapy, adjuvant therapy, or recurrence and metastasis therapy), or the investigator believes that they can be included in this study.

  4. Age ≥18 years; physical condition score ECOG 0~2 points.

  5. Within 4 weeks before enrollment, Neuropathy should be less than grade 2 (NCI CTCAE 5.0).

  6. Within 1 week before enrollment, routine blood examinations were basically normal (based on the normal value of each research center laboratory):

  7. White blood cell count (WBC) ≥3.0×109/L;

  8. Neutrophil count (ANC) ≥ 1.5×109/L;

  9. Platelet count (PLT) ≥100×109/L.

  10. Hemoglobin ≥9g/dL.

  11. Within 1 week before enrollment, liver and kidney function tests were basically normal (the normal value of each research center laboratory is standard):

  12. Total bilirubin (TBIL)≤1.5×upper limit of normal (ULN);

  13. Alanine aminotransferase (SGPT/ALT)≤2.5×ULN (for liver metastases≤5×ULN);

  14. Aspartate aminotransferase (SGOT/AST)≤2.5×ULN (for liver metastases≤5×ULN);

  15. Creatinine clearance rate (Ccr) ≥60 ml/min.

  16. No major organ dysfunction.

  17. The patient must agree to provide blood, urine and stool samples for pharmacokinetic studies, and collect them in strict accordance with the required time points and intervals.

  18. No mental abnormality, able to understand and undertake informed consent.

Exclusion Criteria:
  1. Those who need to receive non-investigative anti-cancer therapy (such as chemotherapy, immunotherapy or biological therapy) during the administration period of this trial.

  2. People who are severely allergic to castor oil, or who have had serious adverse reactions to anti-microtubule drugs in the past.

  3. Within 4 weeks before receiving treatment, have had any major surgery or suffered major trauma; or are expected to undergo major surgery during the treatment.

  4. Pregnancy (positive pregnancy test), breastfeeding patients, or those who are unwilling to use contraception during the test;

  5. Those with uncontrollable intracranial hypertension syndrome (persistent headache, short-term blurred vision, and/or diplopia)

  6. Combined serious diseases, including severe heart disease, cerebrovascular disease, uncontrolled diabetes, uncontrolled high blood pressure, severe infection, active peptic ulcer, etc.

  7. Known HIV infection, or untreated active hepatitis B or C;

  8. Known to have alcohol or drug addiction, or have a history of uncontrollable mental illness, lack of legal capacity or limited legal capacity;

  9. The investigator believes that it is inappropriate to participate in this trial.

  10. Participate in another clinical trial or use other research treatments at the same time.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hunan Cancer Hospital Changsha Hunan China
2 The Third Xiangya Hospital of Central South University Changsha Hunan China

Sponsors and Collaborators

  • Beijing Biostar Technologies, Ltd
  • Chengdu Biostar Pharmaceuticals, Ltd

Investigators

  • Principal Investigator: Quchang Ouyang, MD, Hunan Cancer Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Beijing Biostar Technologies, Ltd
ClinicalTrials.gov Identifier:
NCT05052437
Other Study ID Numbers:
  • BG01-2001
First Posted:
Sep 22, 2021
Last Update Posted:
Sep 22, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 22, 2021